Cargando…
A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment
Dopamine receptor 2 agonists (D2-ags) have been shown to reduce the size of tumors by targeting aberrant angiogenesis in pathological tissue. Because of this, the use of a D2-ag was inferred for endometriosis treatment. When assayed in mouse models however, D2-ags have been shown to cause a shift of...
Autores principales: | Tejada, Miguel Á., Santos-Llamas, Ana I., Fernández-Ramírez, María José, Tarín, Juan J., Cano, Antonio, Gómez, Raúl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001569/ https://www.ncbi.nlm.nih.gov/pubmed/33800198 http://dx.doi.org/10.3390/biomedicines9030269 |
Ejemplares similares
-
Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis
por: Mendoza-Torreblanca, Julieta Griselda, et al.
Publicado: (2023) -
Identification of Altered Evoked and Non-Evoked Responses in a Heterologous Mouse Model of Endometriosis-Associated Pain
por: Tejada, Miguel A., et al.
Publicado: (2022) -
Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report
por: Bouquet de Joliniere, Jean, et al.
Publicado: (2021) -
Rodent Animal Models of Endometriosis-Associated Pain: Unmet Needs and Resources Available for Improving Translational Research in Endometriosis
por: Tejada, Miguel A., et al.
Publicado: (2023) -
Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers
por: Gomez, Raul, et al.
Publicado: (2022)